enVVeno Medical Corp
enVVeno Medical Corp is a U.S.-based medical device company focused on developing bioprosthetic venous valve technologies for severe chronic venous insufficiency. Its lead program, VenoValve, is a surgical replacement venous valve, and its second program, enVVe, is a transcatheter replacement venous valve under development for the deep veins of the leg.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSurgical replacement venous valve designed to restore one-way blood flow in the deep veins of the leg.
Non-surgical, transcatheter-based replacement venous valve intended for deep venous insufficiency.
Research, testing, and clinical trial activities supporting product advancement and regulatory approval.
Customers
The company’s end users are patients with severe chronic venous insufficiency, but the near-term economic customer is the healthcare system and the physicians who adopt the device after regulatory approval. Its products are intended for vascular surgeons, interventional specialists, and hospitals treating advanced venous disease. Because the company is still in development, commercial customers are not yet generating revenue.
They are the ultimate beneficiaries of VenoValve and enVVe, which are designed to improve venous blood flow and reduce symptoms of deep venous reflux.
Vascular and interventional specialists evaluate, implant, and study the devices in clinical trials and will drive adoption after approval.
These facilities would purchase and use the devices for procedural treatment of advanced venous disease once commercialized.
Strategy
The company’s strategy is to advance VenoValve through the FDA appeal and regulatory pathway while continuing clinical development of enVVe. It is also building the evidence package needed to establish a new effectiveness pathway for replacement venous valves, since this category has limited precedent.
Approval is the key gating item for first commercialization and for validating the category.
A second product broadens the platform and reduces dependence on one device program.
Commercial readiness is needed to convert clinical success into revenue after approval.
Geography
enVVeno Medical Corp is headquartered in the United States and conducts its development, regulatory, and clinical activities from the U.S. Its business is currently centered on U.S. FDA pathways, including pivotal study work and IDE-related preparation for its product candidates.
Risks
The company faces high regulatory risk because both products depend on FDA approval and, in VenoValve’s case, on acceptance of a novel effectiveness framework. It also faces development-stage financing risk, since it has no product revenue and must fund clinical trials, regulatory work, and commercialization preparation before any sales begin.
The business depends on FDA clearance/approval for both product candidates, and VenoValve requires acceptance of a new effectiveness pathway.
Exposure: VenoValve and enVVe
Trial outcomes, safety endpoints, and pre-clinical results determine whether the programs can advance.
Exposure: SAVVE study and enVVe GLP/IDE pathway
The company is pre-revenue and relies on external capital to fund R&D and commercialization preparation.
Exposure: Corporate funding needs
Even after approval, physicians and hospitals must adopt a new device category with limited precedent.
Exposure: Future U.S. commercialization
Accounting
Judgemental itemsClinical study costs, professional fees, and personnel costs flow through earnings as incurred and can vary with trial activity.
Impact: Quarterly operating loss
Costs to prepare for commercialization are expensed before sales begin, affecting reported losses without near-term revenue offset.
Impact: Operating expenses
Facility lease commitments create fixed obligations that affect liquidity analysis and balance sheet presentation.
Impact: Cash flow and liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
INVO Fertility, Inc.
IVF · Surgical & Medical Instruments & Apparatus
Enovis CORP
ENOV · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Enovis is a U.S.-based medical technology company focused on orthopedic and musculoskeletal care.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Penumbra Inc
PEN · Surgical & Medical Instruments & Apparatus
Penumbra is a U.S.-based medical device company focused on thrombectomy and related interventional therapies for removing blood clots from the body.
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Last updated: 24/09/2026